The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB)

被引：3
|
作者：
Manns, M. [9 ]
Jeffers, L. [8 ]
Dalekos, G. [7 ]
Berg, T. [6 ]
Trepo, C. [5 ]
Roberts, S. [4 ]
Prieto, M. [3 ]
Rizzetto, M. [2 ]
Sorbel, J. [1 ]
Anderson, J. [1 ]
Mondou, E. [1 ]
Rousseau, F. [1 ]
机构：
[1] Gilead Sci Inc, Durham, NC USA
[2] Univ Turin, Dipartimento Gastroenterol, Turin, Italy
[3] Hosp La Fe, Serv Med Digestiva, E-46009 Valencia, Spain
[4] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[5] Hop Hotel Dieu, Serv Hepatogastroenterol, F-69288 Lyon, France
[6] Charite Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany
[7] Univ Thessaly, Sch Med, Larisa, Greece
[8] Univ Miami, Sch Med, Miami, FL USA
[9] Hannover Med Sch, D-30623 Hannover, Germany
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60076-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
74
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [41] PREDICTORS OF LIVER STIFFNESS CHANGES IN CHRONIC HEPATITIS B (CHB) PATIENTS UNDER LONG-TERM THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Kranidioti, Hariklia
    Protopapas, Adonis A.
    Voulgaris, Theodoros
    Tsolias, Chrisostomos
    Antonakaki, Pinelopi
    Deutsch, Melanie
    Triantos, Christos
    Goulis, John
    Papatheodoridis, George
    Manolakopoulos, Spilios
    GASTROENTEROLOGY, 2021, 160 (06) : S822 - S822
  • [42] Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients
    Dan-Hong Yang
    Yuan-Jun Xie
    Nian-Feng Zhao
    Hong-Ying Pan
    Ming-Wei Li
    Hai-Jun Huang
    World Journal of Gastroenterology, 2015, (09) : 2746 - 2753
  • [43] Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients
    Yang, Dan-Hong
    Xie, Yuan-Jun
    Zhao, Nian-Feng
    Pan, Hong-Ying
    Li, Ming-Wei
    Huang, Hai-Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (09) : 2746 - 2753
  • [44] IMPACT OF PRE-TREATMENT PLASMA HBV DNA LEVELS ON THE RATE OF ALT NORMALIZATION DURING ANTIVIRAL THERAPY WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR CHRONIC HEPATITIS B (CHB)
    Lim, Young-Suk
    Choi, Jonggi
    Choi, Won-Mook
    Brunetto, Maurizia R.
    Hou, JinLin
    Agarwal, Kosh
    Chang, Ting-Tsung
    Ning, Qin
    Lim, Seng Gee
    Streinu-Cercel, Adrian
    Flaherty, John F.
    Wang, Hongyuan
    Gao, Bing
    Gaggar, Anuj
    Suri, Vithika
    Coffin, Carla S.
    Ferrety, Maria Asuncion Buti
    Chan, Henry Lik Yuen
    HEPATOLOGY, 2020, 72 : 485A - 485A
  • [45] Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
    Hong, Hyeyeon
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 49 - 63
  • [46] Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
    Fung, Scott
    Kwan, Peter
    Fabri, Milotka
    Horban, Andrzej
    Pelemis, Mijomir
    Hann, Hie-Won
    Gurel, Selim
    Caruntu, Florin A.
    Flaherty, John F.
    Massetto, Benedetta
    Kim, Kyungpil
    Kitrinos, Kathryn M.
    Subramanian, G. Mani
    McHutchison, John G.
    Yee, Leland J.
    Elkhashab, Magdy
    Berg, Thomas
    Sporea, Loan
    Yurdaydin, Cihan
    Husa, Petr
    Jablkowski, Maciej S.
    Gane, Edward
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : 11 - 18
  • [47] DE NOVO COMBINATION THERAPY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) PLUS LAMIVUDINE (LAM) OR TDF PLUS EMTRICITABINE (FTC) IS ASSOCIATED WITH EARLY VIROLOGIC RESPONSE IN HIV/HBV CO-INFECTED PATIENTS
    Lada, Olivier
    Gervais, Anne
    Branger, Michel
    Peytavin, Gilles
    Collin, Giles
    Fraqueiro, Gil
    Moucari, Rami
    Males, Sylvia
    Martinot-Peignoux, Michelle
    Matheron, Sophie
    Marcellin, Patrick
    HEPATOLOGY, 2008, 48 (04) : 720A - 720A
  • [48] Switching to Tenofovir Disoproxil Fumarate and Lamivudine Combination Therapy in Patients With Chronic Hepatitis B and Poor Response to Adefovir and Lamivudine Combination Therapy
    Mita, Eiji
    Ishida, Hisashi
    Imai, Yasuharu
    Kato, Michio
    Ohta, Hajime
    Shimada, Masaaki
    Nakamuta, Makoto
    Yatsuhashi, Hiroshi
    Masaki, Naohiko
    Suzuki, Yoshiyuki
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S883 - S884
  • [49] Mapping HBsAg epitope profiles to predict HBsAg loss/seroconversion in a treatment naive cohort of genotype A chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) therapy
    Walsh, Renae
    Hammond, Rachel
    Yuen, Lilly
    Bayliss, Julianne
    Revill, Peter A.
    Leary, Thomas
    Thomas, Howard
    Gaggar, Anuj
    Subramanian, Mani
    Kitrinos, Kathryn M.
    Thompson, Alex J.
    Locarnini, Stephen
    HEPATOLOGY, 2015, 62 : 966A - 967A
  • [50] Characterization of HBsAg decline by genotype in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumurate (TDF) for up to 4 years
    Marcellin, P.
    Heathcote, E. J.
    Buti, M.
    Krastev, Z.
    Jacobson, I. M.
    De Man, R.
    Dusheiko, G. M.
    Zeuzem, S.
    Elsome, A. M.
    Barnes, C.
    Ng, C.
    Lou, L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 101 - 102
12345